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ABSTRACT 
AIM OF THE STUDY 
Primary Aim:  To study association between serum lipid levels & severity of 
Diabetic retinopathy 
Secondary Aims: 
To assess the proportion of patients with dyslipidemia among patients with diabetic 
retinopathy 
To assess association between various types of lipoproteins with diabetic 
retinopathy 
MATERIALS AND METHODS 
This is a prospective observational study conducted among patients attending 
Ophthalmology OPD in a tertiary care hospital.It is a cross-sectional,hospital based 
study spanning over a period of 18 months from June 2011 to November 2012.100 
type 2 diabetic patients attending Ophthalmology OPD were examined by 
ophthalmoscopy and fundus fluorescein angiography.Their diabetic retinopathy 
status was graded according to ETDRS classification.Their serum lipid levels were 
assessed.Association between serum lipid levels and retinopathy severity were 
assessed using SPSS software. 
RESULTS: 
In our study the incidence of diabetic  retinopathy was 55% and 45% had no 
features of diabetic retinopathy. In our study, 45% had no signs of diabetic 
retinopathy, 46% had non-proliferative retinopathy and 9% had proliferative 
retinopathy. Mean age in the no diabetic retinopathy group was 54.02,in NPDR 
group it was 57.56 and in the PDR group it was 55.55. According to our study,the 
mean total cholesterol levels are 177.22 in diabetics without retinopathy, 186.86 in 
NPDR and 159.33 in PDR. 20 of the 55 patients (36.3%) with retinopathy had 
elevated serum total cholesterol levels.63.6% of retinopathy patients had desirable 
cholesterol levels.The mean triglyceride levels were calculated as 141.97 in 
diabetics without diabetic retinopathy, 163.13 in NPDR and 195.00 in PDR 
patients. The mean HDL values were 39.73 in diabetics without diabetic 
retinopathy, 36.80 in NPDR and 31.66 in PDR. Mean LDL levels in diabetics 
without diabetic retinopathy was 113.13, 116.04 in NPDR and 99.33 in PDR. 22 of 
55 retinopathy cases (40%) had optimal levels of LDL.Mean glycosylated 
haemoglobin level was 8.12 in diabetics without retinopathy, 8.74 in NPDR AND 
10.00 in PDR . Mean Fasting blood glucose level was 154.22 in diabetics without 
retinopathy, 169.63 in NPDR and 191.11 in PDR. Mean creatinine level was 0.75 
in diabetics without retinopathy, 0.80 in NPDR and 0.86 in PDR. Mean serum 
haemoglobin is 13.33 in diabetics without retinopathy, 13.17 in NPDR and 11.87 
in PDR. 
CONCLUSION: 
No significance was found with severity of diabetic retinopathy and total serum 
cholesterol, serum triglyceride,HDL and LDL levels.Of the retinopathy patients, 
36.3% had elevated serum total cholesterol levels, 70.9% had low HDL and 60% 
elevated LDL levels.No significant association was found between severity of 
diabetic retinopathy and fasting blood glucose levels and also serum creatinine 
levels.There was significant association between glycosylated hemoglobin and 
diabetic retinopathy severity.And also significant negative association with 
haemoglobin levels and severity of diabetic retinopathy 
KEY WORDS: Diabetic retinopathy, cholesterol, HDL, LDL, triglycerides 
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INTRODUCTION 
In the year 2000,the number of people with diabetes in the world was 171 
million.By the year 2030,the numbers are predicted to reach 366 million.In 
India,the prevalence of type2 DM is different in different regions and is 
estimated to be 5-14%. In 2000,31 million were diabetic in India and predicted 
to hike to 79 million by 2030.Thus India is apparently the diabetes capital of the 
world and is likely to remain so for 30 years. 
Diabetics are likely to suffer from various macrovascular and 
microvascular complications of which diabetic retinopathy is a well established 
microvascular complication. Prevalence of Diabetic retinopathy was found to be 
50.3% in USA, 33.6% in UK, 29.0% in Australia and 17.6% in India. 
The large numbers of people affected with DR is an indication of the 
severity of the problem. Various factors have been implicated in the 
development and progression of diabetic retinopathy. 
The association between serum lipid levels and DR have been widely 
studied but has produced conflicting results which may have been because of 
differences in the methodology adapted and also maybe the ethnicity. Our study 
mainly focuses on the South Indian population and thus reducing the errors due 
to changes in ethnicity. 
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Since the visual disability from diabetes is preventable and treatable, 
awareness of the problem and early detection and management can preserve the 
quality of life. If there is a significant role of lipid levels in diabetic retinopathy, 
control of the former could be beneficial for the latter.Our study aims to bring 
out a clearer picture of this scenario in South India. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
Diabetes mellitus is a group of metabolic diseases characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action, or 
both. 1 
Epidemiology 
In the year 2000,the number of people with diabetes in the world was 171 
million.By the year 2030,the numbers are predicted to reach 366 million.In 
India,the prevalence of type2 DM is different to different regions and is 
estimated to be 5-14%.In 2000,31 million were diabetic in India and predicted 
to hike to 79 million by 2030.Thus India is apparently the diabetes capital of the 
world and is likely to remain so for 30 years. 
The reason for the increase in number of cases is predicted to be a result of an 
aging global population, urbanization ,a rising prevalence of obesity, and 
sedentary lifestyles3. 
 Fig. 1. Estimated number of diabetic patients in India in millions 
Types:1 
 1.Type 1 (Insulin dependant diabetes mellitus [IDDM], Juvenile onset diabetes) 
– This develops more commonly between 10 and 20 years of age and presents 
with acute polydipsia, polyuria, nocturia and weight loss. Association with 
HLA-DR3 and HLA-DR4 is seen.Path
of pancreatic islet cells which produce insulin.Type 1 diabetics often manifest a 
total lack of insulin and hence are dependent on external insulin for sugar 
metabolism. 
2.Type 2 (Non-Insulin dependent diabetes mellit
diabetes) – This manifests most frequently by 50
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deficiency of Insulin and/or peripheral insulin resistance.They are often 
asymptomatic and discovered by chance. 
Diagnostic tests for Diabetes1: 
 Fasting blood sugar > 126mg% 
 Random blood sugar >200mg% 
 Glucose tolerance test is performed if diagnosis is uncertain 
 Glycosylated haemoglobin (HbA1C) reflects the average level of blood  glucose 
over the last 6 weeks.Normal value is 4-8%.Values more than this indicates 
inadequate glycemic control. 
 Urine testing for glycosuria is an unsatisfactory method of monitoring diabetic 
control. 
 
Ophthalmic manifestations of Diabetes:4 
1.Ocular conditions directly associated with Diabetes 
• Cataract 
• Anterior Ischemic Optic Neuropathy 
• Diabetic papillopathy 
• Extraocular movements disorders 
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2.Ocular conditions for which diabetes is a known risk factor 
• Glaucoma – Primary open angle and Neovascular 
• Ocular Ischemic syndrome 
3.Ocular conditions for which  diabetes is a possible risk factor 
• Retinal vein occlusion 
• Retinal arteriolar emboli 
• Retinal artery occlusion 
• Corneal disease 
4.Conditions masquerading as diabetic retinopathy in diabetics 
• Age related macular degeneration 
• Hypertensive retinopathy 
• Radiation retinopathy 
 
DIABETIC RETINOPATHY RISK FACTORS 
Diabetic retinopathy (DR) is more common in type 1 DM (40%) when 
compared to type 2 (20%). 
 
1. Duration of Diabetes: Incidence of DR in patients diagnosed with diabetes 
before the age of 30 years,is 50% after 10 years and 90% after 30 years.It rarely 
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develops within 5 years of onset of DM or before puberty though about 5% of 
type 2 DM have DR at presentation.5  
 
2. Control of Blood Glucose: Good glycemic control protects against 
development of retinopathy.Glycosylated Hemoglobin at baseline is a strong 
and independent risk factor or Diabetic Macular edema. DCCT recommends 
intensive therapy to achieve near normal glycemic status as early as possible in 
IDDM patients6. The phenomenon of ongoing beneficial effects on diabetic 
complications after a period of improved glycemic control even if followed by a 
return to usual (often poorer) metabolic control has been described as 
representing "metabolic memory" by the DCCT/EDIC investigators7 and as a 
"legacy effect" by the UKPDS investigators8.Early insulinisation has been 
recommended by Ranjit Unnikrishnan I, Anjana RM, Mohan V based on the 
above concepts9. 
 
3. Hypertension: Patients with DM commonly suffer from concomitant 
hypertension.The Wisconsin Epidemiology Study of Diabetic Retinopathy 
(WESDR) found that patients with type 1 DM had a 17% prevalence of 
hypertension at baseline and a 25% incidence after 10 years10.Among type 2 
DM patients,cross-sectional studies revealed a hypertension prevalence of 38% 
to 68%. 
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Patients with hypertension are more likely to develop DR and even more severe 
levels and have more rapid progression.They are also reported to be upto 3 
times more likely to develop diffuse DME.Both systolic and diastolic pressures 
seem to have an association with DR. A causal relationship between DR and 
hypertension was strongly suggested by the United Kingdom Prospective 
Diabetes Study (UKPDS)11.The UKPDS was a large randomized prospective 
clinical trial evaluating the effects of rigorous BP control in addition to 
glycemic control on the prevention and progression of diabetic vasculopathy in 
patients with type 2 DM.Tight BP control is said to have beneficial effect by 
decreasing the risk of clinical complications from diabetic eye disease.12 The 
UKPDS showed that the incidence of retinopathy was associated with systolic 
blood pressure11,12, while in the WESDR, diastolic blood pressure was a 
significant predictor of progression of diabetic retinopathy to PDR over 14 yr of 
follow up in patients type 1 diabetes10. In the Indian context, hypertension was 
not a significant confounding factor in the CURES Eye study13. 
 
4.Renal Disease: There are extensive cross-sectional and longitudinal studies 
reporting a relationship between proteinuria or microalbuminuria and 
retinopathy. 
In the Microalbuminaria Collaborative Study Group report, retinopathy was not 
a significant independent predictor of albuminaria when adjusted for other 
baseline predictive variables including HbA1c, mean arterial pressure, gender 
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and smoking status14.Some of the effects of renal disease on DR may be 
confounded by blood pressure ( due  to close correlation between kidney disease 
and hypertension) or DM duration due to the high prevalence of DR and other 
coexisting complications with increasing duration of DM. 
Nevertheless the presence and severity of DR are indicators of the risk of gross 
proteinuria as evidenced by the WESDR which revealed that half of all type 1 
DM patients with PDR and 10 or more years of DM had concomitant 
proteinuria.10 The presence of gross proteinuria at baseline is associated with 
95% increased risk of developing DME among type 1 patients in the WESDR. 
Gross proteinuria is a risk indicator for PDR in younger onset DM patients and 
therefore regular eye checkups are advised in that group15. Individuals with 
macroalbuminuria in comparison to microalbuminuria and normoalbuminuria 
showed greater DR prevalence and severity16. 
 
5.Serum lipids : Dyslipidemia,though a clear risk factor in diabetic renal 
disease,its effect on DR and macular edema are less certain. The studies 
conducted on this subject show diverse outcomes. 
ETDRS report 22 states that those diabetics with increased total cholesterol, 
LDL or Triglyceride levels are more likely to have or develop retinal hard 
exudates, which can be associated with risk of vision loss, independent of the 
extent of macular edema.They also stated that the risk was two fold in cases 
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with elevated serum LDL-c  and total cholesterol levels.17Klein et al inferred 
that this relationship was not applicable to type 2 diabetics that did not use 
insulin, and was seen in type 1 diabetics only.18 
According to the DCCT/EDIC cohort the severity of retinopathy was positively 
associated with triglycerides  and negatively associated with HDL cholesterol in 
type 1 diabetics.19The CURES Eye Study showed association of diabetic 
retinopathy with total cholesterol and serum triglycerides and also that diabetic 
macular edema showed a string correlation with high LDL levels.20 
A randomized controlled trial on the role of atorvastatin in diabetic maculopathy 
concluded that there was a decrease in the visible retinal lipid exudates and also 
a positive effect on the visual outcome of affected patients.21 
 FIELD study showed a 30% reduction in laser interventions required in type 2 
diabetic patients receiving fenofibrate, which reduces lipid levels, versus the 
placebo group. 22 These studies therefore show that control of lipid levels could 
help in control of diabetic retinopathy. 
 
6.Pregnancy : Though DR can progress rapidly during pregnancy, this is 
usually a transient progression and long term risk of progression of DR is not 
increased. Both the Diabetes in Early Pregnancy study23,a prospective study of 
140 pregnant diabetic patients, and the DCCT24, a prospective study that 
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included 680 female diabetic patients of child bearing age, found that women 
with poorest glycemic control at baseline and greatest reduction in HbA1C in  
the first trimester were at increased risk of retinopathy progression. Also the 
increasing severity of DR at baseline adversely affects pregnancy outcome, 
including high incidence of pregnancy induced hypertension, obstetrical 
complications, fetal malformations and/or fetal death. A study conducted on 
type 1 diabetics concluded that progression of DR in pregnancy is uncommon 
(5%) but there is a significant increase if duration of DM is more than 10 years 
and also moderate- severe DR at baseline.25 
 
7.Anemia: There have been case reports which show an association between 
anemia and DR. Low hematocrit was an independent risk factor in the ETDRS 
analysis of baseline risk factors for development of high-risk PDR and of severe 
visual loss. In patients with retinopathy, those with low hemoglobin levels had a 
fivefold increased risk of severe retinopathy as compared with those with higher 
hemoglobin levels.26,27,28 
 
8.Genetic factors: Strong associations have been found between proliferative 
retinopathy and presence of HLA-DR phenotypes 4/0, 3/0 and x/x29. ICAM-1 
469KK genotype was associated with a 3.51-fold increased risk for 
retinopathy.30 
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Aldose Reductase Gene (ALR2), Vascular Endothelial Growth Factor Gene 
(VEGF),Receptor for Advanced Glycation End Products Gene (RAGE) are 
some other genes implicated in the development of diabetic retinopathy.31 
 
Retinopathy Factors reducing the prevalence and severity of Diabetic 
Retinopathy : Causes of asymmetric DR :5,32,33 
 
1. Glaucoma : Reduces the prevalence and severity of DR in affected  
eyes.Underlying mechanism is unclear though there are several suggested 
possibilities: 
• Loss of metabolic activity in retina with degeneration of ganglion cells 
secondary to chronic glaucoma. 
• Loss of retinal vascular perfusion secondary to elevated intraocular pressure. 
2. Myopia : Myopia of atleast 5 Dioptres is known to reduce the severity and 
prevalence of DR. 
3. Carotid arery stenosis : Cases of unilateral narrowing of internal carotid artery 
resulting from atherosclerosis has been found to be protecting the ipsilateral eye 
from developing diabetic retinopathy. 
4. Retinochoroidal scarring : Eyes with retinochoroidal scarring from trauma, 
inflammatory diseases etc has markedly reduced prevalence and severity of DR. 
The resultant decreased retinal metabolism and a decreased need for oxygen 
would result in diminished production of angiogenic factors. 
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Epidemiology of Diabetic Retinopathy2,3 
The large numbers of people affected with DR is an indication of the severity of 
the problem. Prevalence of Diabetic retinopathy was found to be 50.3% in 
USA10, 33.6% in UK55, 29.0% in Australia54 and 17.6% in India13. 
Pathogenesis Of Diabetic Retinopathy 32,33,34 
The initiating factor which results in the structural changes of DR is 
hyperglycemia. Hyperglycemia induces these changes due to a combination of 
factors including biochemical, hemodynamic and paracrine factors producing 
structural changes in the vessels including (a) pericytes degeneration 
(b)basement membrane thickening and (c) endothelial cell proliferation. 
 Non-Enzymatic 
glycosylation and 
Advanced Glycation end 
products production
Endothelial apoptosis 
VEGF production
15 
Biochemical Alterations
Increased polyol 
pathway flux
Basement Membrane 
thickening 
Protein kinase C 
Activation
Induces / mediates 
action of VEGF
 
Oxidative stress
Oxygen free radicals 
damage enothelial cells
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Hemodynamic 
alterations
Altered blood flow 
Vasodilation 
Hypercoaguable 
state 
Platelet abnormalities
1. Increased fragility & adhesiveness.
2. Increased endoperoxidases & thromboxane A2
3. Decreased thromboxane
4. Decreased prostacyclin
RBC Abnormalities
1. Decreased ability of RBC's to release oxygen
2. Decreased deformability
3. Increased formation of large aggregates
4. Increased whole blood viscosity
5. Increased adhesiveness to the endothelial cells
Leukocyte Abnormalities 
1. Increased leukocyte adhesions causing andothelial injury 
, VEGF release
17 
 
 
 
Paracrine factors
PRO-ANGLIOGENIC:
VEGF
PDGF
HGF
Erythropoietin
Leptin
Angiogenin
Insulin growth factors 1 and 2
ICAM 1 
Oncofetal fibronectin
Endothelin
Angiopioietin-1
Angiotensin-2
Angiotensin converting enzyme
Complement C4 fragment 
Interleukins (IL-6 , IL-8)
ANTI-ANGIOGENIC:
Endostain
Angiostatin
Pigment epithelium derived factor
Genistein
Thrombospondin 1 
Platelet factor 4 
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Increase in lipid peroxides in blood coupled with weakness of defense 
antioxidant system in diabetics without complication probably serves as a 
background for pathogenesis of endothelial dysfunction associated with diabetes 
mellitus.34 
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CLASSIFICATION OF DIABETIC RETINOPATHY 35 
MODIFIED AIRLIE HOUSE CLASSIFICATION 
ABBREVIATED ETDRS CLASSIFICATION: 
CATEGORY DESCRIPTION MANAGEMENT 
NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) 
No DR Review in 12 months 
Very mild : Microaneurysms only Review most patients in 12 months 
Mild : Any or all of: Microaneurysms, 
retinal hemorrhages, exudates, cotton 
wool spots, up to the level of moderate 
NPDR. No IRMA or significant 
beading 
Review range 6-12 months, depending 
on severity of signs, stability, systemic 
factors, patient’s personal 
circumstances 
Moderate: 
 Severe retinal hemorrhages (more than 
ETDRS standard photograph 2A) 
 Significant venous beading in no more 
than 1 quadrant 
 Cotton wool spots commonly present 
Review in approximately 6 months 
 
Severe 
4:2:1 rule : one or more of : 
Review in 4 months 
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 Severe hemorrhages in all 4 quadrants 
 Significant venous beading in 2 or 
more quadrants 
 Moderate IRMA in 1 or more 
quadrants 
Very Severe 
2 or more of the criteria for severe 
Review in 2-3 months 
PROLIFERATIVE DIABETIC RETINOPATHY (PDR) 
MILD-MODERATE 
New vessels on disc (NVD) or new 
vessels elsewhere (NVE),but extent 
insufficient to meet high risk criteria 
Treatment considered according to 
severity of signs, stability, systemic 
factors, patient’s personal 
circumstances. 
If not treated, review in 2 months  
HIGH RISK 
 New vessels on disc (NVD) greater 
than ETDRS standard photograph 10A 
(about 1/3 disc area) 
 Any NVD with vitreous or preretinal 
hemorrhage 
 NVE greater than ½ disc area with 
vitreous or preretinal hemorrhage (or 
Immediate treatment 
21 
 
hemorrhage with presumed obscured 
NVD/E) 
Advanced diabetic eye disease 
Tractional retinal detachment, 
significant persistent vitreous 
hemorrhage and neovascular glaucoma 
Immediate treatment 
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CLINICAL FEATURES 5,32,33 
NON-PROLIFERATIVE DIABETIC RETINOPATHY 
It is the most common form of diabetic retinopathy. Opthalmoscopically the 
following findings may be seen. 
MICROANEURYSMS 
They are caused by hypercellular out pouching of the capillary walls due to loss 
of pericytes. Mostly located within the inner nuclear layer,they appear as small 
red dots with sharp margins and are less than 1/12 the diameter of an average 
optic disc or 125u in its longest dimension. Their diameter varies between 12-
100u, however only those greater than 30u can be visualized with direct 
ophthalmoscope. On fluorescein angiography ,these microaneurysms are seen as 
hyperfluorescent dots that fill during early venous phase and remain 
hyperfluoresent during the late phase without any change in size or others may 
become larger with leakage of dye in the surrounding tissue. Most of these are 
located in posterior pole with a predisposition for the area temporal to the fovea. 
These microaneurysms undergo a thickening and hyalinization of the walls over 
a period of time resulting in “auto-occlusion” and they appear yellow or white 
in color. Most of the microaneurysms are present adjacent to the area of 
capillary non-perfusion (CNP) and as the area of CNP advances, these 
microaneurysms may disappear. 
  
 
FIGURE 2: FUNDUS COLOR PHOTOGRAPH 
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RETINAL HEMORRHAGES 
The wall of capillary or microaneurysm may rupture and cause intraretinal 
bleeds. These hemorrhages may be seen in the superficial or deep layers of 
retina and acquire specific shapes according to the situation. Those in 
superficial layers assume flame shape as the nerve fibers run parallel to the 
surface of the retina and are thus called flame shaped or splinter hemorrhages. 
They are the result of superficial capillary bleeds due to raised arterial pressure. 
They generally absorb in 3 months time. 
In the deeper layers (outer plexiform and inner nuclear layers) the cells are 
arranged perpendicular to the retinal surface, therefore bleeding in this area are 
round or oval in shape and thus termed ‘dot and blot’ hemorrhages. They are 
usually more than 1/12 the diameter of an average optic disc or greater than 
125u in its longest dimension and usually have irregular margins and/or uneven 
density. Their color depends on the oxygen contents, those with greater amounts 
of oxyhemogloblin appear red whereas those with lesser amounts appear darker. 
Fundus fluorescein angiography can be used to differentiate them from 
microaneurysms. Hemorrhages appear as hypofluorescent areas due to blocked 
fluorescence. Intraretinal hemorrhages cause visual disturbance only if located 
in foveolar region. Blot haemorrhages tend to appear in clusters indicating 
underlying capillary closure and therefore is an important indicator of 
progression of retinopathy. 
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HARD EXUDATES 
These are actually lipid accumulations that leak from abnormal vessels. They 
appear as glistening, yellowish white in color with waxy appearance and sharp 
margins. Mostly located in outer plexiform layer, though they may be more 
superficial especially in presence of retinal edema. They may be scattered 
throughout the macula or accumulate in the form of circinate ring around the 
microaneurysms and such a pattern is referred to as “circinate retinopathy”. The 
circinate rings are seen at junction of abnormal and normal retina. These hard 
exudates get absorbed by phagocytosis and thus disappear over a period of 
months to years. The macrophages clearing these hard exudates migrate through 
the retina into adjacent normal capillaries. 
COTTON WOOL SPOTS 
Also known as soft exudates, they represent nerve fiber layer infarcts and are 
caused by occlusion of pre capillary arterioles that result in retinal axonal 
swelling due to accumulation of intracellular fluid or organelles secondary to 
impaired axoplasmic flow in the area of capillary non-perfusion. They appear 
round or oval with pale yellow-white or grayish-white color and less than half a 
disc diameter with fluffy appearance and feathery borders. On fluorescein 
angiography,they appear as areas of capillary non-perfusion, usually lined by 
microaneurysms. Their mean life is 3-17months and they disappear earlier in 
younger patients. Those associated with hypertension disappear earlier. On 
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resolution, the nerve fibers and ganglion cells of the inner retina become 
atrophic and depressed producing a “Depression sign”. There may be a transient 
increase in the number in patients who are initiated on insulin therapy and 
brought under tight metabolic control. 
INTRARETINAL MICROVASCULAR ABNORMALITIES (IRMA) 
These are narrow, tortuous intraretinal vascular segment that are thought to 
represent : (a) dilated capillaries that function as collateral channels during 
hypoxia or (b) new vessel growth within the retina. Their presence indicates 
severe form on NPDR with an impending risk of developing retinal 
neovascularisation. 
Some differentiating features between IRMAs and preretinal new vessels 
include: 
• Neovascularization tends to form a cart-wheel like network 
• New vessels extend across both arterial and venous branches of underlying 
vessels 
• New vessels may show accompanying fibrous proliferation 
• Biomicroscopic retinal examination shows more superficial location of 
preretinal new vessels 
• FFA shows profuse leakage from new vessels whereas IRMAs do not leak 
 
26 
 
VENOUS CHANGES 
Severe retinal hypoxia and sluggish circulation results in venous caliber 
abnormalities characterized by venous dilatation, beading and loop formation. 
Transient dilatation of veins may be seen in hyperglycemia, even in the absence 
of any retinopathy and may represent a preclinical stage of diabetic retinopathy. 
The localized variation in venous caliber is typical of diabetic retinopathy and is 
designated as venous beading while the venous loops are hairpin or semicircular 
deviations of the vein from its normal course. On fluorescein angiography, there 
are areas of capillary non-perfusion adjacent to these venous changes, thus 
indicating ischemia. 
 
FEATURELESS RETINA 
In the late stage of the NPDR, larger arterioles may occlude completely 
resulting in extensive capillary non-perfusion. Retina may appear thin and 
atrophic and does not show any background lesions. This may result in 
underestimation of the actual severity of the disease. Careful evaluation has to 
be done for occluded arterioles and areas of avascular retina that is thinner and 
duller compared to healthy retina. Fluorescein angiography reveals extensive 
areas of capillary non-perfusion. This is an important sign as these patients may 
develop neovascularisation of iris and angle without showing any retinal 
vascularisation. 
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PROLIFERATIVE DIABETIC RETINOPATHY (PDR) 
PDR is characterized by proliferation of new vessels on the optic disc (NVD) or 
elsewhere (NVE).It indicates more severe form of the disease reflecting marked 
underlying ischemia.The vascular bed adjacent to the area of new vessels dilates 
and may be a stimulus for new vessel formation.Both ischemia and a dilated 
capillary bed act as a trigger for initiating the process of angiogenesis. 
 
  
 FIGURE 3: FUNDUS COLOR PHOTOGRAPH SHOWING NEOVASCULARISATION OF DISC 
FIGURE 4: FUNDUS COLOR PHOTOGRAPH SHOWING NEOVASCULARISATION ELSEWHERE   
 FIGURE 5: FUNDUS COLOR PHOTOGRAPH SHOWING SUBHYALOID HEMORRHAGE 
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METHODS OF RETINAL EXAMINATION 5,32,33 
Various methods can be used to evaluate retinal changes in diabetic retinopathy. 
1.DIRECT OPHTHALMOSCOPY 
Though an easy and convenient method, its two main disadvantages are the lack 
of a stereoscopic view of structural changes which are three dimensional by 
nature and the difficulty of recording and transmitting the information or of 
making any form of quantitative assessment of the disturbance. 
2.INDIRECT OPHTHALMOSCOPY 
This is more useful in patients with opacities in the ocular media. Good 
illumination and wide field of view make this the instrument of choice for 
examining retina in detail upto the periphery. Indentation will give view of the 
peripheral retina. 
3.SLIT LAMP BIOMICROSCOPY 
The fundus viewing contact lens allows examination of the posterior vitreous 
and posterior pole of the fundus  with the slit lamp microscope. Goldmanns lens 
is commonly used and is a plano-concave contact lens. It is used during laser 
photocoagulation and during vitrectomy. The central zone of 3 mirror contact 
lens can also be used as a fundus viewing lens. 
By 90D or 78D condensing lenses, the real image of the retina formed by the 
condensing lenses may be viewed through slit lamp microscope. The 90D lens 
gives a wider field of view but lesser magnification than the 78D lens. Though 
it gives an excellent view of the posterior pole of the fundus, it is less suitable 
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for examining the periphery of retina. It gives a stereoscopic view of the 
macula. The panfundoscopic contact lens gives a panoramic view of the retina. 
4.FUNDUS PHOTOGRAPHY 
Grading of retinopathy can be done with the help of fundus photographs and the 
progression or the effect of treatment can be assessed by serial photographs. 
In this study I used the Zeiss FF450 Plus camera to take fundus photographs. 
5.FLUORESCEIN ANGIOGRAPHY (FFA) 
This allows us to examine structures in the retina which are beyond the limit of 
direct ophthalmoscopy and also enables the study of hemodynamic changes that 
occur in the retina and the localised abnormalities of flow and perfusion that are 
the background for many pathological disturbances. 
Under normal circumstances the contrast medium fluorescein,does not leak out 
of the retinal vessels.Abnormal fluorescence in an angiogram may be due to: 
(1) Hyperfluorescence 
• Leakage of dye from microaneurysms, IRMA, new vessels and from damaged 
capillaries 
• Leakage from optic nerve head in NVD 
• Staining of tissues as a result of prolonged retention of fluorescein 
(2) Hypofluorescence 
• Blockage of fluorescence by increased density of pigment (xanthophyll), hard 
exudates and blood 
 FIGURE 6 : FUNDUS FLUORESCEIN ANGIOGRAM 
 FIGURE 7 : FUNDUS FLUORESCEIN ANGIOGRAM 
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• Obstruction of circulation preventing access of fluorescein to the tissues 
resulting in areas of capillary nonperfusion. This is a very good indicator of 
retinal ischemia which will lead to development of neovascularisation. 
FFA is an excellent method of showing retinal capillaries and a good guide for 
laser photocoagulation and to assess the effect of treatment.Neovascularisation 
elsewhere occurs usually at the junction of perfused and non-perfused retina and 
the most common location is along the temporal vascular arcades.36 
5. ELECTRO DIAGNOSTIC TESTS (ERG) 
It is the record of an action potential produced by the retina when it is 
stimulated by light of adequate intensity. 
It is useful in assessing retinal function in diabetic retinopathy, when the media 
is opaque due to cataract or vitreous hemorrhage. 
6. ULTRASOUND ‘B’ SCAN 
In DR, it is used when the media is opaque to detect whether there is any 
vitreous hemorrhage, posterior vitreous detachment, traction or rhegmatogenous 
retinal detachment or to detect the presence of epiretinal membranes. 
• Vitreous opacities produce dots or short lines. 
• Membranous lesions produce an echogenic line.  
7. VISUAL ACUITY 
It is the most important test of macular function, particularly for near. 
Hypermetropia, with disparity between the subjective and objective refraction 
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of the eye, is characteristic of a shallow elevation of sensory retina at macula. In 
CSMO, near visual acuity is affected. 
8. AMSLER GRID 
Evaluates the 20 degrees of visual field surrounding fixation. It is primarily 
used for screening macular function. 
9. PHOTOSRESS TEST 
May be useful in demonstrating macular lesions when ophthalmoscopy is 
equivocal in early cystoid macular edema. 
10. POTENTIAL ACUITY METER 
This is done by projecting a standard Snellen’s chart onto the macula through a 
small area of an immature cataract and asking the patient to read the letters. 
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TREATMENT OF DIABETIC RETINOPATHY 37,38 
First and a very essential step is control of diabetes.This is very important in 
preventing development of microvascular complications.The main modes of 
treatment of diabetes mellitus are: 
1.INSULIN THERAPY 
This is the mainstay in youth onset diabetes and maturity onset diabetes,in 
whom oral hypoglycaemic agents have failed to maintain satisfactory blood 
sugar levels. 
Available insulin preparations are: 
• Rapid acting preparations – for intravenous, intramuscular and subcutaneous 
use with peak activity of 2-4hrs. 
• Intermediate acting preparations – such as NPH (Isophane) and Lente (Zinc) 
with a 6-12 hr span of peak activity. 
• Long acting preparations – such as ultra lente and protamine zinc insulin (PZI) 
with 14-24 hrs span of maximal action. 
• Human Insulin- synthetic insulin with a structure identical to that of human 
hormone has largely replaced animal insulins. It is produced either by chemical 
synthesis or by recombinant DNA techniques. It is less antigenic. 
Regimen of meticulous control 
• Intensified multiple subcutaneous insulin injections 
• Continuous subcutaneous insulin infusion 
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• Implantable intraperitoneal pumps 
Risk of meticulous control 
Acceleration of diabetic retinopathy- though not a common complication, 
amelioration of severe retinopathy cannot be expected. According to DCCT 
study, the progression of early retinopathy slowed down.BDR is not a 
contraindication for meticulous control, but frequent ophthalmologic 
surveillance is required to detect accelerated neovascularisation. The reason for 
worsening is unknown. Perhaps retinal glucopenia may stimulate vascular 
endothelial growth factor (VEGF).VEGF receptors are present in endothelial 
cells of retina and of major vessels. 
2.DIET THERAPY 
Normal weight persons with diabetes usually require about 35kcal/kg body 
weight/day and 0.8-1gm protein/kg body wt/day. A standard recommendation is 
for fat content to be 30% or less of total calories and for saturated fat to be in 
the range of 7-10%. 
3.EXERCISE 
4.ORAL HYPOGLYCEMIC AGENTS 
• SULPHONYL UREAS –Glipizide, Glimepride, Glyburide 
• BIGUANIDES – Metformin 
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• MEGLITINIDES – Nateglinide, Repaglinide 
• THIAZOLIDINEDIONES – Pioglitazone, Rosiglitazone 
• α – GLUCOSIDASE INHIBITORS – Acarbose, Miglitol 
• DPP-IV INHIBITORS - Sitagliptin 
 
SPECIFIC TREATMENT FOR DIABETIC RETINOPATHY 
• Laser Photocoagulation  
• Surgical – Vitrectomy, Intravitreal Injections 
 
 
LASER PHOTOCOAGULATION 
It is recommended that patients with severe and very severe NPDR must receive 
laser treatment when exposed to several risk factors that can influence 
progression of disease. 
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Risk factors for laser treatment39: 
NON-MODIFIABLE Diabetes Mellitus type I 
Opposite eye with PDR 
Extensive zones of capillary closure on FFA 
MODIFIABLE Glycemic control 
Elevated serum lipids 
Hypertension 
Renal dysfunction 
TIMEABLE Pregnancy 
Cataract in evolution 
Strict glycemic control 
Irregular followup 
 
Macular photocoagulation for CSME are of two types 5,36: 
1.Focal – for leaking microaneurysm 
2.Grid – for diffuse macular edema 
Since the visual outcome following grid laser is poor, surgical intervention is 
preferred instead. Focal laser for CSME should precede Pan retinal 
photocoagulation by 6-8 weeks ideally. 
Panretinal photocoagulation is usually done in 2 or more sessions to prevent 
macular edema. In the first session, inferior quadrants are done and in the 
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second session, the superior quadrants and also open macular closure are done. 
More sessions may be added if required. 
ETDRS  RESEARCH GROUP PROTOCOL FOR PRP40 
Spot size 500microns 
Exposure time 0.1s 
Intensity Moderate 
Number of shots 1200 – 1600 
Location Diameter of shot separation, >2DD out of fovea 
to the equator 
Number of sessions At least 2 
Treated lesions directly New vessels 2DD extrapapillary 
Indications for new treatment Areas of new vessels extrapapillary, high risk 
PDR, recurrence 
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SURGICAL THERAPY 
Pars Plana Vitrectomy: 
Current indications for vitrectomy in diabetic eye disease41 
• Severe non-clearing vitreous hemorrhage. 
• Tractional retinal detachment involving macula 
• Combined tractional and rhegmatogenous detachment 
• Severe progressive fibrovascular proliferation 
• Dense pre-macular hemorrhage 
• Macular edema associated with or without posterior hyaloid 
traction 
• Diffuse macular edema with massive hard exudates 
• Ghost cell glaucoma 
• Anterior hyaloidal fibrovascular proliferation 
• Fibrinoid syndrome with associated retinal detachment. 
The diabetic retinopathy vitrectomy study (DRVS) demonstrated that early 
vitrectomy (1-4 months after onset of severe vitreous hemorrhage cause  <5/200 
vision) resulted in a slightly higher proportion of cases achieving a final vision 
of ≥20/40. The difference was more marked for the subgroup of patients with 
Type-I DM, indicating that the optimal timing for vitrectomy in severe vitreous 
hemorrhage in type I diabetes is sooner, around 3 months after onset.42 
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Vitrectomy with Internal Limiting membrane peeling at macula in cases of 
diabetic macular edema is done with the main objective being relieving the 
traction of ILM on macular area leaving retinal tissue force to settle and absorb 
the edema.43,44 Prompt, rather than early vitrectomy, is indicated in a subgroup 
of patients characterized by presence of a dense pre-retinal hemorrhage 
confined within an incomplete PVD overlying the area centralis.45 
 
Intravitreal Injections: 
Intravitreal Triamcinolone acetonide (IVTA) during vitrectomy or given alone 
is reported to cause short term regression of diabetic macular edema and 
increase visual acuity. IVTA after 6 months or less leads to prolonged beneficial 
improvement of vision.46,47 Posurdex is a biodegradable, extended-release 
dexamethasone implant that has shown promising outcomes in the treatment of 
macular edema of various etiologies including diabetic macular edema.48 
 
Anti-VEGF antibodies like Bevacizumab (Avastin), Pegaptanib (Macugen), 
Ranibizumab (Lucentis) are widely used nowadays for the treatment of 
neovascularisation in DR. 
VEGF is produced by pericytes, the pigment epithelial cells, and endothelial 
cells of the retina in response to hypoxia from capillary loss and/or 
microaneurysm formation. Clinical studies have shown that intravitreal VEGF 
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concentration increased in eyes as they progressed from nonproliferative 
diabetic retinopathy to active proliferative diabetic retinopathy 49. 
 
Protein Kinase C (Pkc) Inhibitors like LY333531 (ruboxistaurin, RBX) and 
PKC412 (midostaurin) are currently being studied for the treatment of DR. 50,51 
 
Octreotide (a somatostatin analog) and Sandostatin (growth hormone/insulin-
like growth factor-1 antagonist) decreased the need for retinal photocoagulation 
compared with conventional treatment in a study .52 
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OVERVIEW OF LIPIDS 
The word cholesterol is derived from Greek words, ‘chole’-bile and ‘steros’- 
solid, ‘ol’- alcohol. 
LDL transports cholesterol from liver to peripheral tissues and is thus called 
‘bad cholesterol’.75% of plasma cholesterol is incorporated into LDL 
particles.HDL transports cholesterol from peripheral tissues to liver (reverse 
cholesterol transport) and so called ‘good cholesterol’. 
NCEP-ATP GUIDELINES III ON CLASSIFICATION OF LIPIDS53 
LDL <100 
100-129 
130-159 
160-189 
>= 190 
Optimal 
Near/above Optimal 
Borderline high 
High 
Very High 
CHOLESTEROL <200 
200-239 
>= 240 
Desirable 
Borderline high 
High 
HDL <40 
>= 60 
Low 
High 
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AIM OF THE STUDY 
 
Primary Aim:  To study association between serum lipid levels & severity 
of Diabetic retinopathy 
 
Secondary Aims: 
1. To assess the proportion of patients with dyslipidemia among patients 
with diabetic retinopathy 
 
 
2. To assess association between various types of lipoproteins with 
diabetic retinopathy 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 MATERIALS AND METHODS
 
 This is a prospective observational study conducted among patients 
attending Ophthalmology OPD in PSG Institute of Medical Sciences and 
Research Centre,Coimbatore.
 It is a cross-sectional,hospital based study spanning over a period of 18 
months from June 2011 to Nov
 Study design  
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ember 2012. 
100 Diabetic Patients
Ophthalmoscopy
& FFA
Grade Diabetic Retinopathy 
according to ETDRS grading 
system
Serum lipid levels assessed
Assess association between 
Serum lipid levels & Diabetic 
Retinopathy severity
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 Inclusion criteria: 
  Type II Diabetes Mellitus     
 Age >40yrs 
 Either sex 
 Duration of Diabetes 5-15years 
 Exclusion criteria: 
Hazy media like Corneal opacity,Cataract, Vitreous 
hemorrhage 
Already existing retinal diseases other than diabetic 
retinopathy 
Factors that retard progression of DR-High myopia,advanced 
glaucoma 
Factors that accelerate the progression of DR- Severe 
anemia,renal disease,hypertension 
 100 patients fitting into the inclusion and exclusion criteria were selected 
and a complete ophthalmological examination was done at presentation 
and included ophthalmoscopy and Fundus Fluorescein Angiogram. 
 Their retinopathy status was then graded according to the ETDRS 
Grading System. 
 Blood was collected and estimation of FBS, Lipid profile, Hb, Creatinine, 
HbA1C was done. 
 The data collected was then analysed using SPSS software. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION & RESULTS 
 OBSERVATION AND RESULT
INCIDENCE 
 
NO. OF CASES 
PERCENTAGE 
 
In our study the incidence of diabetic  retinopathy was 55%
features of diabetic retinopathy.
WITH 
RETINOPATHY
55%
INCIDENCE OF DIABETIC RETINOPATHY
45 
 
DM WITHOUT 
RETINOPATHY 
DM WITH 
RETINOPATHY
45 55 
45% 55% 
 and 45% had
WITHOUT 
RETINOPATHY
45%
 
 
 no 
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STAGING OF DIABETIC RETINOPATHY 
 NO DR NPDR PDR 
NO. OF CASES 45 46 9 
PERCENTAGE  45% 46% 9% 
 
 
In our study, 45% had no signs of diabetic retinopathy, 46% had non-
proliferative retinopathy and 9% had proliferative retinopathy. 
  
45 46
9
0
5
10
15
20
25
30
35
40
45
50
NO RETINOPATHY NPDR PDR
STAGES
 AGE DISTRIBUTION 
AGE IN 
YEARS 
NO 
RETINOPATHY
40-50 20 
51-60 14 
61-70 9 
71-80 2 
TOTAL 45 
 
Mean age in the no diabetic retinopathy group was 54.02,in NPDR group it was 
57.56 and in the PDR group it was 55.55.There was no significant association 
0
2
4
6
8
10
12
14
16
18
20
40-50
20
13
3
47 
 
NPDR PDR 
13 3 
12 5 
17 1 
4 0 
46 9 
51-60 61-70 71-80
14
9
2
12
17
4
5
1
NO DR NPDR PDR
TOTAL 
36 
31 
27 
6 
100 
 
0
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between increasing age and diabetic retinopathy status according to this study      
(p-value 0.195).  
 SEX DISTRIBUTION 
SEX NO DR
MALE 32 
FEMALE 13 
TOTAL 45 
 
Of the 100 consecutive patients included in the study,65 were male and 35 
female.In all 3 groups males predominated but in
was smaller as 5 of the PDR cases were males and the other 4 were females.
MALE
32
28
49 
 NPDR PDR 
28 5 
18 4 
46 9 
 the PDR group the sex ratio 
FEMALE
13
18
5
4
NO DR NPDR PDR
TOTAL 
65 
35 
100 
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TOTAL CHOLESTEROL 
 No DR NPDR PDR 
MEAN 177.22 186.86 159.33 
STANDARD 
DEVIATION 
41.15 52.12 47.74 
P VALUE 0.24 
 
According to our study,the mean total cholesterol levels are 177.22 in diabetics 
without retinopathy, 186.86 in NPDR and 159.33 in PDR.However since the p 
value is 0.24, there was no significance found with serum cholesterol levels and 
severity of diabetic retinopathy. 
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CHOLESTEROL LEVELS IN RETINOPATHY PATIENTS 
 RETINOPATHY TOTAL 
NPDR PDR 
NCEP-ATP 
classification 
of 
CHOLESTEROL 
<200 
(Desirable) 
27 8 35 (63.6%) 
200-239 
(Borderline 
high) 
13 0 13 (23.6%) 
≥240 
(High) 
6 1 7 (12.7%) 
TOTAL  46 9 55 
 
20 of the 55 patients (36.3%) with retinopathy had elevated serum total 
cholesterol levels.63.6% of retinopathy patients had desirable cholesterol levels. 
 
 
 
 
  
52 
 
TRIGLYCERIDES 
 No DR NPDR PDR 
MEAN 141.97 163.13 195.00 
STANDARD 
DEVIATION 
68.87 86.05 192.50 
P VALUE 0.243 
 
The mean triglyceride levels were calculated as 141.97 in diabetics without 
diabetic retinopathy, 163.13 in NPDR and 195.00 in PDR patients.There was no 
significant association between serum triglyceride levels and severity of diabetic 
retinopathy with p value being 0.24. 
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HDL 
 No DR NPDR PDR 
MEAN 39.73 36.80 31.66 
STANDARD 
DEVIATION 
15.01 10.32 12.43 
P VALUE 0.19 
 
The mean HDL values were 39.73 in diabetics without diabetic retinopathy, 
36.80 in NPDR and 31.66 in PDR.Again there was no significant correlation 
between serum HDL levels and diabetic retinopathy severity (p-value 0.19). 
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HDL LEVELS IN RETINOPATHY PATIENTS 
 RETINOPATHY TOTAL 
NPDR PDR 
NCEP-ATP 
classification 
of HDL 
<40 
(Low) 
32 7 39 (70.9%) 
40-59 12 2 14 (25.4%) 
≥60 
(High) 
2 0 2 (3.6%) 
TOTAL  46 9 55 
 
39 of 55 (70.9%) retinopathy patients had low HDL levels and only 2 (3.6%) 
had high HDL levels which is desirable.  
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LDL 
 No DR NPDR PDR 
MEAN 113.13 116.04 99.33 
STANDARD 
DEVIATION 
40.10 47.87 42.24 
P VALUE 0.58 
 
Mean LDL levels in diabetics without diabetic retinopathy was 113.13, 116.04 
in NPDR and 99.33 in PDR.There was no significant correlation between serum 
LDL levels and severity of diabetic retinopathy (p-value 0.58). 
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LDL LEVELS IN RETINOPATHY PATIENTS 
 RETINOPATHY TOTAL 
NPDR PDR 
NCEP-ATP 
classification 
of LDL 
<100 
(Optimal) 
18 4 22 (40%) 
100-129 
(Near 
optimal) 
13 2 15 (27.3%) 
130-159 
(Borderline 
High) 
10 3 13 (23.6%) 
160-189 
(High) 
0 0 0 (0%) 
≥190 
(Very high) 
5 0 5 (9%) 
TOTAL  46 9 55 
 
22 of 55 retinopathy cases (40%) had optimal levels of LDL.Very high levels 
were seen only in NPDR cases in our study.   
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HBA1C 
 No DR NPDR PDR 
MEAN 8.12 8.74 10.00 
STANDARD 
DEVIATION 
1.95 2.02 2.11 
P VALUE 0.03 
 
Mean glycosylated haemoglobin level was 8.12 in diabetics without 
retinopathy, 8.74 in NPDR AND 10.00 in PDR . There was significant 
correlation between glycosylated haemoglobin levels and staging of diabetic 
retinopathy (0.03).  
58 
 
FASTING BLOOD GLUCOSE 
 No DR NPDR PDR 
MEAN 154.22 169.63 191.11 
STANDARD 
DEVIATION 
60.27 79.76 81.03 
P VALUE 0.30 
 
Mean Fasting blood glucose level was 154.22 in diabetics without retinopathy, 
169.63 in NPDR and 191.11 in PDR.There was no significant correlation found 
between fasting blood glucose levels and severity of diabetic retinopathy (p 
value 0.30).  
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CREATININE 
 No DR NPDR PDR 
MEAN 0.75 0.80 0.86 
STANDARD 
DEVIATION 
0.17 0.17 0.20 
P VALUE 0.16 
 
Mean creatinine level was 0.75 in diabetics without retinopathy, 0.80 in NPDR 
and 0.86 in PDR.There was no significant correlation found between serum 
creatinine levels and diabetic retinopathy (p-value 0.16).  
60 
 
HEMOGLOBIN 
 No DR NPDR PDR 
MEAN 13.33 13.17 11.87 
STANDARD 
DEVIATION 
1.59 1.57 2.16 
P VALUE 0.05 
 
Mean serum haemoglobin is 13.33 in diabetics without retinopathy, 13.17 in 
NPDR and 11.87 in PDR.There was significant association with anemia and 
severity of diabetic retinopathy with p-value 0.05. 
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DISCUSSION 
 
Of the 100 Type 2 diabetic patients included in this study, diabetic 
retinopathy was detected in 55%.The results are consistent with the Wisconsin 
Epidemiological Study for Diabetic Retinopathy conducted in the USA among 
1313 subjects where 50.3% had diabetic retinopathy. However WESDR study 
was conducted among type I diabetics.10 
In the Blue Mountain Eye Study (BMES)54 conducted in Australia and 
the Liverpool Diabetic Eye Study55 conducted in the United Kingdom, the 
prevalence of diabetic retinopathy was 29% and 33.6% each.  
In the Chennai Urban Rural Epidemiological Study I (CURES I) which is 
an ongoing study conducted in India the prevalence of diabetic retinopathy in 
the 1715 subjects was 17.6% which is considerably lower than the above studies 
conducted in Western countries.13 
In this study mean age in the no diabetic retinopathy group was 54.02,in 
NPDR group it was 57.56 and in the PDR group it was 55.55.There was no 
significant association between increasing age and diabetic retinopathy status 
according to this study (p-value 0.195). 
Of the 100 consecutive diabetic patients included in our study, 65 were 
male and 35 were female. In all 3 groups males predominated but in the PDR 
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group the sex ratio was smaller as 5 of the PDR cases were males and the other 
4 were females. According to CURES13, UKPDS56 and Hyderabad Study57 
males were affected more. 
According to our study, the mean total cholesterol levels are 177.22 in 
diabetics without retinopathy, 186.86 in NPDR and 159.33 in PDR. However 
since the p-value is 0.24, there was no significant association found between 
serum lipid levels and severity of diabetic retinopathy. 20 of the 55 patients with 
retinopathy (36.3%) had elevated serum total cholesterol levels and 63.6% of 
retinopathy patients had desirable cholesterol levels. 
The mean triglyceride levels were calculated as 141.97 in diabetics 
without diabetic retinopathy, 163.13 in NPDR and 195.00 in PDR patients. 
There was no significant association between serum triglyceride levels and 
severity of diabetic retinopathy with p value being 0.24. 
The mean HDL values were 39.73 in diabetics without diabetic 
retinopathy, 36.80 in NPDR and 31.66 in PDR. Again there was no significant 
association between serum HDL levels and diabetic retinopathy severity (p-
value 0.19). 39 of 55 (70.9%) retinopathy patients had low HDL levels and only 
2 (3.6%) had high HDL levels which is desirable. 
Mean LDL levels in diabetics without diabetic retinopathy was 113.13, 
116.04 in NPDR and 99.33 in PDR. There was no significant association 
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between serum LDL levels and severity of diabetic retinopathy (p-value 0.58). 
22 of 55 retinopathy cases (40%) had optimal levels of LDL. Very high levels 
were seen only in NPDR cases in our study.  
The lower levels of total cholesterol and LDL in the PDR group in our 
study could be attributed to the increased awareness of their medical condition 
and thus more vigorous measures to achieve control of blood parameters in that 
group. 
ETDRS report 22 states that those diabetics with increased total 
cholesterol, LDL or Triglyceride levels are more likely to have or develop 
retinal hard exudates, which can be associated with risk of vision loss, 
independent of the extent of macular edema. They also stated that the risk was 
twofold in cases with elevated serum LDL-c and total cholesterol levels17.Klein 
et al inferred that this relationship was not applicable to type 2 diabetics that did 
not use insulin, and was seen in type 1 diabetics only18. This is consistent with 
our study which was conducted on type 2 diabetics. 
Dhir, Dahiya et al conducted a study in North India and concluded that 
though the cholesterol profile values were slightly elevated in the diabetic 
retinopathy group, there was no significant difference noted.58 
Mohan R, Mohan V, Susheela L, Ramachadran A, Viswanathan M et al 
concluded that the mean serum total cholesterol and LDL levels and also the 
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mean total/HDL cholesterol and mean LDL/HDL cholesterol ratios were 
significantly increased in diabetic maculopathy group as compared to the no 
retinopathy group. It was also reported that the mean serum HDL and VLDL 
cholesterol and the triglyceride levels were similar in both groups.59 
Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, 
Klein RL reported in 2004 that severity of retinopathy was positively associated 
with triglycerides  and negatively associated with HDL cholesterol in type 1 
diabetics.19 
Rema et al in 2005 showed association of diabetic retinopathy with total 
cholesterol and serum triglycerides and also that diabetic macular edema 
showed a strong correlation with high LDL levels.20 
Gupta A, Gupta V, Thapar S, Bhansali A conducted a randomized 
controlled trial on the role of atorvastatin in diabetic maculopathy and 
concluded that there was a decrease in the visible retinal lipid exudates and also 
a positive effect on the visual outcome of affected patients. They also confirmed 
that exudates may reduce or resorb within weeks of starting statin treatment and 
even before or without the need for argon laser photocoagulation.21 
FIELD study showed a 30% reduction in laser interventions required in 
type 2 diabetic patients receiving fenofibrate, which reduces the serum lipid 
levels, versus the placebo group.22 
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Mean glycosylated haemoglobin level was 8.12 in diabetics without 
retinopathy, 8.74 in NPDR AND 10.00 in PDR . There was significant 
association between glycosylated haemoglobin levels and staging of diabetic 
retinopathy (0.03). 
Mean Fasting blood glucose level was 154.22 in diabetics without 
retinopathy, 169.63 in NPDR and 191.11 in PDR. There was no significant 
association found between fasting blood glucose levels and severity of diabetic 
retinopathy (p value 0.30). 
The CURES6  and WESDR10 all report that the level of hyperglycemia 
influences the development and progression of diabetic retinopathy. The 
WESDR and DCCT6 studies in type 1 and UKPDS56 study in type 2 showed 
protective role of glycemic control in prevention and non-progression of 
diabetic retinopathy. In the CURES Eye Study, for every 2% elevation of 
HbA1c level, the risk of diabetic retinopathy increased by a factor of 1.7 and in 
the UKPDS study, for every 1% reduction of HbA1c, the risk reduction in eye 
complications was 19%. 
The phenomenon of ongoing beneficial effects on diabetic complications 
after a period of improved glycemic control even if followed by a return to 
usual (often poorer) metabolic control, has been described as representing 
"metabolic memory" by the DCCT/EDIC investigators7 and as a "legacy effect" 
by the UKPDS investigators8.Early insulinisation has been recommended by 
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Ranjit Unnikrishnan I, Anjana RM, Mohan V based on the above concepts9.This 
shows the importance of long term control of blood sugar which is also proved 
in our study. 
Mean creatinine level was 0.75 in diabetics without retinopathy, 0.80 in 
NPDR and 0.86 in PDR.There was no significant association found between 
serum creatinine levels and diabetic retinopathy (p-value 0.16). 
Several studies have demonstrated association between nephropathy and 
diabetic retinopathy though they have mainly focused on the albuminuria and 
proteinuria levels. We however have considered serum creatinine in our study 
and excluded all those with elevated serum creatinine levels. Proteinuria was 
reported in 29.2% of DR patients in the CURES Eye Study60. WESDR10 also 
showed association between microalbuminuria and Mohan et al reported that 
PDR was more prevalent in macroproteinuria than in microproteinuria27. 
Mean serum haemoglobin is 13.33 in diabetics without retinopathy, 13.17 
in NPDR and 11.87 in PDR.There was significant negative association with 
haemoglobin levels and severity of diabetic retinopathy with p-value 0.05. 
Anemia is a known risk factor for diabetic retinopathy and the reason 
suggested is the availability of smaller amounts of oxygen for the retinal tissue. 
Spontaneous closure of microaneurysms has been reported by Singh et al on 
correction of anemia and metabolic control in type 1 diabetics61. ETDRS also 
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reported low hematocrit as an independent risk factor for high risk PDR 
development and visual impairment26. Qiao Q et al reported a fivefold risk of 
diabetic retinopathy severity in patients with low hemoglobin levels. In our 
study we have excluded patients with anemia.62 
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NEED FOR THE STUDY 
The need for such a study is because of the conflicting results seen in the 
older studies on the association between diabetic retinopathy and lipid levels. 
Our study mainly focuses on the South Indian population and thus reducing the 
errors due to changes in ethnicity. If there is a significant role of lipid levels in 
diabetic retinopathy, control of the former could be beneficial for the latter. The 
role of lipid level control in the prevention and retardation of progress of DR in 
our population is also assessed in our study.  
 
 
LIMITATIONS OF THE STUDY 
The drawback of our study is the limitation of the study group size as it 
does not portray a large proportion of the population. Since only those patients 
attending the Ophthalmology OPD are included in the study,all those who did 
not seek medical attention have been missed.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
1. Diabetic retinopathy was detected in 55%. 
2. In our study, 45% had no signs of diabetic retinopathy, 46% had non-
proliferative retinopathy and 9% had proliferative retinopathy. 
3. No significant association between increasing age and diabetic 
retinopathy status is seen. 
4. Of the 100 consecutive diabetic patients included in the study,65 were 
males and 35 were females.In all 3 groups males predominated in this 
study with a decreased male:female ratio in the PDR group. 
5. No significance was found with total serum cholesterol levels and 
severity of diabetic retinopathy. 
6. 36.3% of patients with retinopathy had elevated serum total cholesterol 
levels. 
7. There was no significant association between serum triglyceride levels 
and severity of diabetic retinopathy. 
8. Again there was no significant association between serum HDL levels 
and diabetic retinopathy severity. 
9. 70.9% of retinopathy patients had low HDL. 
10. There was no significant association between serum LDL levels and 
severity of diabetic retinopathy. 
11. 60% of retinopathy cases had elevated LDL levels. 
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12. There was significant association between glycosylated haemoglobin 
levels and staging of diabetic retinopathy. 
13. There was no significant association found between fasting blood glucose 
levels and severity of diabetic retinopathy. 
14. There was no significant association found between serum creatinine 
levels and diabetic retinopathy. 
15. There was significant negative association with haemoglobin levels and 
severity of diabetic retinopathy. 
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CASE SHEET PROFORMA 
Name: 
Age: 
Sex: 
Address: 
IP No. : 
 
Presenting complaints: 
H/o Presenting illness: 
Past History: 
1)Diabetes Mellitus 
2)Hypertension 
3)Any other systemic illness 
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Treatment History: 
Any Oral Hypoglycemic agents or Insulin- 
Any lipid lowering drungs- 
Any other drugs- 
History of laser treatment in eyes- 
History of any intraocular injections- 
History of ocular surgeries- 
Family History: 
Personal History: 
Smoking- 
Alcohol- 
Physical activity- 
Diet- 
Systemic Examination: 
Blood pressure- 
Ocular Examination: 
Visual acuity-  
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  *Uncorrected- 
  *With Pinhole- 
  *Best corrected- 
  *Near Vision- 
Eyelids and adnexa- 
Conjunctiva- 
Cornea- 
Anterior Chamber- 
Iris- 
Pupil- 
Lens- 
Extraocular movements- 
Posterior segment examination- 
 *Ophthalmoscopy- 
 *Fundus Fluorescein Angiography- 
Tension- 
Gonioscopy- 
84 
 
Other Investigations: 
a) FBS 
b) Serum lipid profile 
c) HbA1C 
d) Hb 
e) Serum creatinine 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
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SR. 
NO 
NAME AGE SEX HOSP. NO. DIAB. RET. STATUS FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
1 CHANDRIKA 56 F O09094296 RE-PDR 
LE-Mod NPDR 
287 159 158 23 106 12.5 12.7 0.73 
2 PALANISAMY 
N.K. 
72 M O11072956 BE- No  DR 90 150 137 48 73 12.9 6.3 2.16 
3 NAGARAJ 51 M O11079451 BE- No  DR 190 161 158 38 89 14.6 6.7 0.72 
4 RAJADURAI 47 M OO422922 BE- No  DR 262 216 247 38 140 14.4 10.24 0.73 
5 KANNAN S.P. 54 M O11079330 BE- No  DR 141 154 147 34 96 13.9 10.97 0.83 
6 RAMESH 
KUMAR 
44 M O11082216 BE- No  DR 195 175 35 113 93 13.2 9.2 0.85 
7 MUNIYANDI 
P. 
55 M O08031315 BE- PDR 210 150 140 39 141 13.2 11.9 0.9 
8 SADAYAPPAN 
P. 
61 M O11083058 BE- No  DR 162 197 229 39 134 15.4 8.23 1.22 
9 DAICY 47 F O06025684 RE- No  DR 
LE- PDR 
301 194 190 32 131 12.8 12.7 0.49 
10 JAGADESAN 
K.S. 
62 M O11091550 BE- Mod NPDR 
with Maculopathy 
261 170 141 33 135 13.9 10.2 1.0 
11 GOWRI KALA 40 F O11090881 RE- No  DR 
LE- Mild NPDR 
235 150 105 30 100 11.9 10.4 0.48 
12 FATHIMA 
BEEBI 
53 F O02209828 BE- Mild NPDR 259 120 116 40 90 12.3 11.0 1.01 
13 LAKSHMI R. 61 F O03016408 BE-Mod NPDR with 
Maculopathy 
95 106 82 38 42 12.5 7.2 1.02 
14 POUJINISHA 42 F O12005885 RE-No DR 
LE-Mild NPDR 
137 166 140 38 91 12.1 7.0 0.86 
15 SRIRAMALU 77 M O12004036 RE-No NPDR 
LE-Mild NPDR 
138 157 282 29 91 11.8 7.0 1.37 
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SR. 
NO 
NAME AGE SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
16 SHANMUGA 
DURAI 
68 M O11093013 BE- No  DR 105 160 171 35 87 12.4 6.8 0.79 
17 BALA 
SUNDARAM 
67 M O04045592 BE- No  DR 132 127 184 23 76 14.1 7.8 0.88 
18 LAKSHMI N. 65 F O02024399 BE- Mod NPDR 
with Maculopathy 
113 170 67 61 96 13.1 7.0 0.68 
19 BALAKRISHNAN 63 M O08094907 BE- No  DR 85 157 114 39 96 12.5 5.96 1.1 
20 GUNASEKHARAN 
T. 
60 M O05011197 BE- No  DR 107 128 71 37 74 10.8 5.5 0.79 
21 PREMA DORTHY 50 F O12023197 BE- No  DR 132 220 142 60 146 12.9 9.0 0.62 
22 VELUSAMY P. 52 M O00019018 BE- Mod NPDR 131 274 201 33 192 13.9 8.1 0.68 
23 CHELLAMMAL P. 66 F O12027554 RE-Maculopathy, 
LE- Mod NPDR 
363 131 126 42 81 12.7 13.01 0.58 
24 DHARMARAJ A. 47 M O11091830 RE-Mild NPDR, LE- 
No DR 
188 281 117 58 201 14.7 9.36 0.67 
25 S. KAMALAM 55 F O10002061 BE- No  DR 138 194 74 49 139 14.8 6.4 0.54 
26 RAJESHWARI 55 F O12030419 RE-Severe NPDR, 
LE- PDR 
144 158 93 28 116 10.7 8.22 1.1 
27 IRUDAYA MARY 75 F O11042516 BE- PDR 73 115 287 5 23 8.4 7.9 1.0 
28 KULANDAIRAJ 63 M O12076177 BE-Mod NPDR 
with Maculopathy 
183 219 158 37 150 12.3 8.7 1.1 
29 NOORJAHAN 55 F O13041234 BE-No DR 198 315 218 46 235 12.9 9.6 0.51 
30 NAVANEETHA 
KRISHNAN 
50 M O13041232 BE- PDR 233 270 672 37 157 16.1 10.2 0.72 
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SR. 
NO 
NAME AG
E 
SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
31 MYILSAMY M. 50 M O13041464 RE- Mild NPDR 
LE- No DR 
146 224 411 42 49 16.5 9.5 0.76 
32 ARUKKANI D. 45 M O13041524 BE-No DR 190 178 102 32 126 10.9 7.8 0.7 
33 THAMBURAJ 50 M O13041707 BE-Mild NPDR 226 99 64 42 49 15.7 10.5 0.71 
34 JAYAMANI 57 F O13036972 BE- Severe NPDR 92 132 160 35 65 11.1 14.1 0.66 
35 RAMASAMY K 53 M O13042737 BE- No DR 72 172 134 33 114 12.1 6.2 0.60 
36 MARUTHAM P 46 M O13042725 BE- No DR 226 196 174 27 138 15.1 7.4 0.76 
37 JALAJI RANI 63 F O13043582 RE-Mild NPDR 
LE-No DR 
205 210 144 68 124 12.2 9.8 0.53 
38 YOGARAJAN 47 M O13020917 BE-No DR 310 175 95 35 119 16.2 11.4 0.94 
39 SELVARAJ ME  47 M O13044672 BE-No DR 145 122 110 29 74 12.0 7.0 0.64 
40 PAPATHY P 70 F O13044719 BE-No DR 155 269 171 60 184 13.1 8.3 0.51 
41 SHANMUGASUN
DAR 
58 M O09053976 BE-Mild NPDR 131 117 144 30 69 15.1 6.9 0.67 
42 SURULIVEL R 63 M O13043895 BE-Mild NPDR 218 128 229 9 76 14.3 7.3 1.00 
43 NURULYAHASAN 63 F O13044389 BE-No DR 151 158 218 3 3 10.4 6.72 1.00 
44 STANIESLAUS 44 M O07014978 BE-MILD NPDR 92 194 145 38 129 14.5 6.8 0.9 
45 IRUDIYA SAMY 63 M O13041484 BE-MILD NPDR 110 158 137 31 107 13.2 7.1 1.1 
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SR. 
NO 
NAME AG
E 
SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
46 SAKTHIVEL RP 43 M O11047558 BE-NO DR 123 115 93 33 67 14 6.6 1.06 
47 MARIMUTHU 45 M O13049181 BE-SEVERE NPDR 91 182 140 37 125 14.4 8.9 1.1 
48 GANDHIMATHI 53 F O13049769 BE-MILD NPDR 240 202 152 36 116 12.6 9.2 0.9 
49 SHANMUGHAM 
MK 
48 M O12013812 BE-NO DR 123 182 101 39 128 16.6 7.7 1.0 
50 NATCHIMUTHU 49 M O11015543 BE-MOD NPDR 188 310 210 40 225 10.8 9.9 0.73 
51 BHAGAVATHI 
GOUNDER 
62 M O12064736 BE-MILD NPDR 155 146 135 36 78 13.9 6.5 0.78 
52 SUBRAMANIAM 
PK 
68 M O13045589 BE- NO DR 110 176 91 34 133 15.9 6.3 0.76 
53 PADMINI P 55 F O13045581 BE-NO DR 211 228 215 47 161 12.6 7.5 0.47 
54 THANGARAJ 65 M O12023260 BE-MILD NPDR 96 180 75 47 140 10.9 12.57 1.07 
55 ARUMUGAM 60 M O13013656 BE-NO DR 200 168 96 25 117 13.4 13.7 0.85 
56 SAROJA 61 F O13045877 BE-NO DR 167 193 146 44 137 11.1 8.5 0.55 
57 AMIRTHAM 50 F O08026524 BE-No DR 368 142 153 39 86 12.0 12.4 0.68 
58 SAJANI N  44 F O13042804 RE-MILD NPDR 
LE-NO DR 
294 247 97 44 194 12.0 11.9 0.67 
59 RADHAKRISHNA
N 
61 M I11026435 BE-PDR with 
MACULOPATHY 
237 127 71 31 78 10.9 7.16 0.96 
60 KANDASWAMY 65 M O11083813 BE-SEVERE NPDR 
with 
MACULOPATHY 
278 170 91 29 114 12.4 9.7 0.68 
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SR. 
NO 
NAME AG
E 
SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
61 PERUMAL A  57 M O10101592 BE-PDR 122 134 70 45 72 10.4 10.6 1.10 
62 PARAMASIVAM 60 M O06057850 BE-MILD NPDR 99 220 153 38 149 11.8 7.4 1.0 
63 BALASUBRAMAN
IAM 
61 M O07023989 BE-MILD NPDR 121 146 89 29 98 13.8 6.2 0.83 
64 SAKTHIVEL K 46 M O12012837 BE-SEVERE NPDR 230 225 400 43 118 15.0 8.5 0.8 
65 LALITHA 56 F O12032046 BE-MOD NPDR 118 216 455 31 110 12.2 7.8 0.69 
66 THANGAVEL 64 M O13040862 BE-MILD NPDR 137 188 161 44 119 14.4 8.7 0.79 
67 SHANMUGASUN
DARAM 
58 M O09053976 BE-MILD NPDR 131 117 144 30 69 15.1 7.6 0.67 
68 SANTHA 
BALAKRISHNAN 
76 F O13046848 BE-MILD NPDR 130 228 200 38 128 11.8 7.5 0.89 
69 GEETHA A 49 F O13046653 BE-NO DR 75 198 78 43 124 12.8 9.4 0.78 
70 PADMAVATHY 72 F O96006352 BE-MILD NPDR 128 220 84 39 136 12.6 7.9 0.9 
71 SANTHA 
BALAKRISHNAN 
76 F O13046848 BE-MILD NPDR 130 228 200 38 128 11.8 6.8 0.89 
72 DHANALAKSHMI 67 F O12087322 BE-MOD NPDR 133 240 212 37 130 12.0 7.3 0.59 
73 MANIKANDAN 45 M O13046810 BE-NO DR 135 143 109 31 93 13.0 6.6 0.87 
74 AISAMMA 60  F O10076711 BE-NO DR 130 188 121 37 109 12.1 8.1 0.75 
75 VISWANATHAN 58 M O13046829 BE-MILD NPDR 84 194 130 35 64 12.6 6.1 0.68 
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SR. 
NO 
NAME AG
E 
SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
76 RAVIKUMAR K 57 M O13046813 BE-NO DR 156 198 378 29 109 14.5 9.3 0.78 
77 ANWAR BASHA 66 M O13047405 MILD NPDR 112 202 193 30 151 15.6 8.7 0.76 
78 ANAND KUMAR J 43 M O13046184 MOD NPDR WITH 
MACULOPATHY 
88 198 173 23 147 14 6.6 0.65 
79 RAHMATHULLA 40 M O13047970 NO DR 189 185 182 34 128 14 9.7 0.53 
80 MAHESWARI 58 F O13046257 NO DR 187 267 214 45 201 12.6 10.2 0.53 
81 ABDUL JABBAR 74 M O10010064 NO DR 168 148 168 41 88 12.9 12.4 0.70 
82 ABBAS 42 M O12051027 NO DR 99 124 69 59 57 14.3 6.1 0.8 
83 POONGODI 40 F O09057256 NO DR 141 160 123 33 102 11.1 7.4 0.8 
84 MR 
RAMAKRISHNAN 
63 M O05039626 NO DR 121 164 109 32 112 13.4 7.0 1.1 
85 CHINNASAMY 59 M O13046451 NO DR 109 147 70 33 105 14.0 5.6 0.82 
86 PONNUSAMY 
GOUNDER 
54 M O00004980 MOD NPDR 461 322 183 35 259 14.2 13.07 0.9 
87 PARIMALAM 57 M O13048721 NO DR 122 139 93 39 92 13.5 7.5 0.41 
88 KALAIARASAN 51 M O13048733 MILD NPDR 112 208 93 42 158 15.4 7.1 0.58 
89 THARABANU 46 F O12007204 NO DR 96 130 65 55 53 12.8 6.5 0.71 
90 KUMARASAMY 49 M O09107105 NO DR 103 164 107 36 124 10.9 6.6 0.72 
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SR. 
NO 
NAME AG
E 
SEX HOSP. NO. DIAB. RET. 
STATUS 
FBS T.CHOL TG HDL LDL Hb HBA1C CREAT 
91 GRACY MOSES 68 F O12000399 MILD NPDR 148 122 132 37 69 11.2 7.9 0.81 
92 SATHIYANARAYA
NA 
45 M O13020603 NO DR 182 184 115 45 100 11.5 8.7 0.74 
93 PALANIAPPAN 48 M O13048982 NO DR 234 246 341 39 167 17.2 10.2 0.77 
94 MEYYAPPAN 54 M O13035545 NO DR 98 176 119 39 130 13.9 6.5 0.65 
95 PALANIAMMAL 52 F O13035575 MILD NPDR 92 170 134 40 116 13.3 6.4 0.50 
96 VELUSAMY 42 M O13013500 NO DR 107 186 102 39 132 15.3 7.7 0.65 
97 LAKSHMI 55 F I13020725 MOD NPDR 191 173 291 6 29 10.2 10.78 0.9 
98 DEVARAJ 61 M O11060264 MILD NPDR 245 205 137 37 148 16.5 9.84 0.75 
99 RAMASAMY 45 M O13049513 SEVERE NPDR 248 131 71 38 83 11.7 10.30 0.85 
100 BASKARAN A 44 M O12022613 PDR 113 127 74 45 70 11.9 8.7 0.80 
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ABBREVIATIONS 
 
DM: DIABETES MELLITUS 
IDDM : INSULIN DEPENDENT DIABETES MELLITUS 
NIDDM : NON-INSULIN DEPENDENT DIABETES MELLITUS 
DR: DIABETIC RETINOPATHY 
NPDR: NON PROLIFERATIVE DIABETIC RETINOPATHY 
PDR: PROLIFERATIVE DIABETIC RETINOPATHY 
DME: DIABETIC MACULAR EDEMA 
CSME: CLINICALLY SIGNIFICANT MACULAR EDEMA 
IRMA : INTRA RETINAL MICROVASCULAR ABNORMALITIES 
NVD : NEOVASCULARISATION OF DISC 
NVE : NEOVASCULARISATION ELSEWHERE 
FBS: FASTING BLOOD SUGAR 
PPBS: POST PRANDIAL BLOOD SUGAR 
HBA1C: GLYCOSYLATED HAEMOGLOBIN 
TGL: TOTAL TRIGLYCERIDES 
TC : TOTAL CHOLESTEROL 
HDL : HIGH DENSITY LIPOPROTEIN 
LDL : LOW DENSITY LIPOPROTEIN 
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HB: HEMOGLOBIN 
ETDRS : EARLY TREATMENT DIABETIC RETINOPATHY STUDY 
BMES : BLUE MOUNTAIN EYE STUDY 
CURES : CHENNAI URBAN RURAL EPIDEMIOLOGICAL STUDY 
WESDR : WISCONSIN EPIDEMIOLOGY STUDY OF DIABETIC 
RETINOPATHY 
DCCT / EDIC : THE DIABETES CONTROL AND COMPLICATIONS 
TRIAL/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND 
COMPLICATIONS RESEARCH GROUP 
UKPDS : UNITED KINGDOM PROSPECTIVE DIABETES STUDY 
 
